HOME > TOP STORIES
TOP STORIES
-
REGULATORY NHI-Market Price Gap at 8.8%, 6.8% Price Cut Expected in FY2016 Revision
December 3, 2015
-
REGULATORY MHLW Discussing Use of Disease Registry as Substitute for Control Groups; Could Be “One Means of Evaluation” in Trials for Rare Diseases
December 2, 2015
-
BUSINESS Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
-
BUSINESS Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
-
TRENDS AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
REGULATORY Evaluation of Efficacy Was Challenging in Sakigake Pick, Designating All Qualified Drugs Desirable: MHLW Official
November 27, 2015
-
REGULATORY Drug Pricing Debate to Culminate in December; Abraxane, Zosyn Major Candidates for Market Expansion Re-Pricing
November 26, 2015
-
REGULATORY Don’t Seek Near-Term Profits but Have Long-Term Vision, MHLW Official Tells Drug Makers
November 25, 2015
-
REGULATORY MHLW Eyes Using HTA to Re-Price Drugs with Big Sales Outlooks That Have Gone Through 1 or 2 Price Revisions
November 24, 2015
-
ACADEMIA Viekirax Joins Fray in Hep C Market, Can It Crack into Harvoni’s Stronghold?
November 20, 2015
-
ORGANIZATION Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
-
REGULATORY AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
November 18, 2015
-
BUSINESS Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
-
BUSINESS AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
-
REGULATORY Business Improvement Order Issued to Novartis Japan
November 13, 2015
-
REGULATORY Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
-
BUSINESS Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
-
REGULATORY Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
-
REGULATORY Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
-
BUSINESS Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
November 6, 2015
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…